HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy

This article was originally published in The Tan Sheet

Executive Summary

Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.

You may also be interested in...

Japan's Takeda Reportedly Offering $12B For Europe's Nycomed

The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.

P&G/Teva Joint Venture Lays Foundation For Switches, Product Launches

Procter & Gamble and Teva Pharmaceutical Industries combine their consumer businesses in a joint venture that creates a leading platform for Rx-to-OTC switches and new consumer health products.

Reckitt Continues Asian Push With $724M Paras Purchase

Reckitt Benckiser continues expanding its Asian business with the purchase of Paras Pharmaceuticals Ltd., a top OTC manufacturer in India, where nonprescription drug sales are growing 23% annually.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts